National Center for Health Research testifies against the approval of a new first of its kind drug for postpartum depression called Brexanolone.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Here are our Statements and Positions on issues that affect you.
NCHR Testimony on the Opioid Buprenorphine/Samidorphan for Depression
November 1, 2018. The clinical trial data do not provide adequate evidence that buprenorphine/samidorphan reduces the symptoms of depression. There are concerns about it potential for long-term harms to patients and others who might misuse or abuse it. BUP/SAM needs to provide strong evidence of efficacy before approval.
Read More »NCHR Comments on the FDA’s Post-Marketing Pediatric-Focused Product Safety Reviews
NCHR Comments on the FDA’s Post-Marketing Pediatric-Focused Product Safety Reviews
Read More »NCHR Testimony at the FDA’s Pediatric Advisory Committee Meeting
NCHR testified at the FDA’s pediatric advisory committee meeting to have better labeling on side effects for important psychiatric drugs used in children and adolescents.
Read More »NCHR Testimony on Prucalopride for Chronic Idiopathic Constipation
NCHR testifies against approving prucalopride at the FDA. Data shows that studies showing the efficacy and safety of this drug are from 1999 and have less than 10% of racial minorities in their clinical trials.
Read More »